News

Hosted on MSN1mon
Abcuro secures $200m as it eyes approval for rare muscle disease drug
US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis (IBM). The funding round ...
Hosted on MSN5mon
Samantha Ruth Prabhu Finds A 'Sweet Spot' In Managing Myositis, Reacts To 'Another Weight Comment'
Myositis is classified into several forms, including Dermatomyositis (DM), Polymyositis (PM), Necrotizing myopathy (NM), Inclusion body myositis (IBM), Juvenile forms of myositis (JM), and ...